Spain's Sanchez Visits China to Deepen Trade Ties Amid U.S. Tensions 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Bank of America Maintains Forecast for Two Fed Rate Cuts in 2026 Despite Inflation Risks 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
U.S. Blockades Strait of Hormuz as Oil Prices Surge Past $100 
BCA Research Warns U.S.-Iran Ceasefire Could Collapse, Maintains Cautious Equity Outlook 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
U.S. Natural Gas Market Faces Short-Term Pressure but Long-Term Demand Surge 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Iran War Fallout: How Sri Lanka, Pakistan, and Egypt Are Struggling With Rising Energy Costs 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Celltrion has completed the third phase of its COVID-19 drug testing after administering the experimental coronavirus antibody treatment to 1,300 individuals who participated in this stage of the clinical trial.
The COVID-19 drug under trial
As per The Korea Herald, this phase 3 is the final step in the human tests of the medicine that was named Regkirona or CT-P59. It was mentioned that the trials are being done in 13 nations that include the U.S., South Korea, Romania, and Spain.
Based on the report, the said drug has been approved in Korea for emergency use and was issued an authorization in February. It was then used to treat patients with mild symptoms in adults and those belonging to high-risk groups. Celltrion shared that they did not find any unusual reaction from a group of patients who received the drug.
The next step for the Korean biopharmaceutical company based in Incheon is to gather the results of the tests and forward them to overseas and local health authorities. Celltrion may do this within the last week of June this year.
“Celltrion has secured enough patients for phase 3 clinical study and expects to speed up discussions to export the COVID-19 antibody treatment,” a company official said. “We will focus on successfully completing the phase 3 clinical trial by the first half this year.”
The company is said to have already produced enough doses of the tested drug for 100,000 people. And once Celltrion secured all the necessary documents and approval for Regkirona, it has the capacity to produce the treatment for at least three million people per year.
Celltrion’s board welcomes the founders’ sons
Meanwhile, Celltrion founder Seo Jung Jin’s two sons have reportedly joined the company’s board of non-listed holding entities. The move was done to prepare for the second-generation management and generational shift. The sons’ entrance to Celltrion’s board also comes after Seo resigned last year.
Maeil Kyeongje News reported that the eldest son, Seo Jin Seok, will be taking the vacated seat of his father as the board chairman of Celltrion Holdings. He was also assigned as the head of the company’s managing board last month during a shareholder’s meeting.
Finally, Seo Joon Serk, the younger brother of Jin Seok, will be the board director of Celltrion Healthcare Holdings, the largest shareholder of Celltrion Healthcare that was established only last year.
